Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1995-8-17
|
pubmed:abstractText |
Salmeterol may be useful in the treatment of asthmatic patients requiring high-dose inhaled steroids, and there have been debates about its anti-inflammatory action. We have compared the efficacy and effects on serum inflammatory markers, including soluble interleukin 2R (sIL-2R), eosinophil cationic protein (ECP), and tryptase of salmeterol and albuterol in 20 patients with moderate to severe asthma who were all receiving high-dose inhaled corticosteroids and inhaled beta 2-agonist on demand. After a 2-week run-in period, they received, in a randomized, crossover, double-blind and placebo-controlled manner, either salmeterol, 50 micrograms twice a day, or albuterol 400 micrograms, four times a day, from a powder inhaler during two 2-week treatment periods, separated by a 2-week washout. Compared with albuterol, salmeterol treatment was associated with better morning and mean peak expiratory flow (p = 0.013 and 0.016, respectively), less daytime and nocturnal symptoms (p = 0.008 and 0.01, respectively), reduced requirement of rescue albuterol (p = 0.04), and better efficacy rating by patients (p = 0.04). However, serum concentration of sIL-2R was significantly higher during regular albuterol treatment (p = 0.014) but no differences were seen in the concentrations of ECP and tryptase between the two treatment periods. We conclude that inhaled salmeterol, 50 micrograms twice daily, confers a better control of asthma than albuterol, 400 micrograms four times daily, in patients with moderate to severe disease, and the latter treatment may be associated with increased T-lymphocyte activation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adrenal Cortex Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Adrenergic beta-Agonists,
http://linkedlifedata.com/resource/pubmed/chemical/Albuterol,
http://linkedlifedata.com/resource/pubmed/chemical/Prednisolone,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/salmeterol
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0012-3692
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
108
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
36-40
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:7606988-Administration, Inhalation,
pubmed-meshheading:7606988-Adrenal Cortex Hormones,
pubmed-meshheading:7606988-Adrenergic beta-Agonists,
pubmed-meshheading:7606988-Albuterol,
pubmed-meshheading:7606988-Asthma,
pubmed-meshheading:7606988-Cross-Over Studies,
pubmed-meshheading:7606988-Double-Blind Method,
pubmed-meshheading:7606988-Forced Expiratory Volume,
pubmed-meshheading:7606988-Humans,
pubmed-meshheading:7606988-Peak Expiratory Flow Rate,
pubmed-meshheading:7606988-Prednisolone,
pubmed-meshheading:7606988-Receptors, Interleukin-2,
pubmed-meshheading:7606988-Treatment Outcome
|
pubmed:year |
1995
|
pubmed:articleTitle |
Inhaled salmeterol and albuterol in asthmatic patients receiving high-dose inhaled corticosteroids.
|
pubmed:affiliation |
Department of Medicine, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|